CD44 is one of the most versatile cell surface receptors in biology. In one context it anchors migrating lymphocytes to inflamed endothelium. In another it marks a subpopulation of tumor cells with stem-like properties and resistance to therapy. In clinical samples it appears in elevated soluble form in the plasma of patients with several cancer types. Tracking it with a validated cd44 elisa kit allows researchers to study all of these roles quantitatively in human samples.

CD44: A Brief Overview

CD44 is a transmembrane glycoprotein encoded by a single gene but expressed in multiple isoforms through extensive alternative splicing of up to ten variant exons (v1–v10). The standard isoform (CD44s) is expressed on most cells; highly glycosylated variant isoforms (CD44v) are often associated with pathological or activated states, particularly in cancer.

Its primary ligand is hyaluronan (HA), a glycosaminoglycan abundant in the extracellular matrix. Hyaluronan-CD44 binding activates signaling pathways — including PI3K/AKT, MAPK, and FAK — that promote cell survival, proliferation, and migration. CD44 also interacts with osteopontin, matrix metalloproteinases, and growth factor receptors, making it a central node in the tumor microenvironment.

Cancer Stem Cell Biology

The use of CD44 as a cancer stem cell marker has profoundly shaped tumor biology research. Breast cancer stem cells were initially characterized as CD44+/CD24- — a phenotype linked to tumor-initiating capacity, epithelial-to-mesenchymal transition, and resistance to chemotherapy. Similar CD44-high populations have been identified in colorectal, pancreatic, ovarian, and head-and-neck cancers.

Soluble CD44 (sCD44) — shed from the cell surface through metalloprotease activity — is measurable in serum and plasma. Elevated sCD44 has been associated with cancer stage and metastatic burden in several tumor types, suggesting its potential as a liquid biopsy component.

Inflammatory and Immune Applications

In immunology, CD44 marks activated and memory T cells. As naïve T cells respond to antigen and differentiate into effectors and memory cells, CD44 surface expression increases sharply. This makes CD44 a widely used marker for distinguishing naïve from experienced T-cell populations in mouse and human studies.

In inflammatory diseases including rheumatoid arthritis and inflammatory bowel disease, elevated sCD44 has been observed in joint fluid and serum. CD44-hyaluronan interactions contribute to leukocyte recruitment to inflamed tissue, and measuring sCD44 provides a window into the systemic inflammatory state.

Using the ELISA for Human Samples

A cd44 elisa kit captures sCD44 from serum or plasma using an antibody pair optimized for human CD44. Key considerations include:

• Isoform coverage: Whether the kit detects all isoforms or preferentially the standard form. In cancer research, isoform-specific detection may be important depending on the research question.

• Sample matrix: Serum and plasma give different results due to differences in protein content. Most kits specify which is preferred and provide guidance on expected concentration ranges.

• Dilution optimization: sCD44 levels in cancer patient plasma can be substantially elevated; samples may need serial dilution to fall within the linear range of the assay.

• CD44 in Wound Healing and Tissue Repair

Beyond cancer and immunology, CD44 plays underappreciated roles in tissue homeostasis and repair. In wound healing, fibroblasts and keratinocytes upregulate CD44 expression and migrate along hyaluronan-rich provisional matrix toward the wound site. CD44 engagement with hyaluronan in this context promotes cell motility and survival signals that accelerate tissue closure.

In fibrotic diseases — including pulmonary fibrosis, liver fibrosis, and kidney fibrosis — CD44 contributes to the activation of fibroblasts into myofibroblasts, the cells responsible for excessive collagen deposition. Measuring CD44 in tissue samples from fibrosis models or patient biopsies by IHC, and in plasma by ELISA, helps researchers understand how CD44-driven signaling contributes to disease progression and how it might be modulated therapeutically.

Hyaluronan fragmentation during tissue damage generates low-molecular-weight hyaluronan (LMW-HA) that binds CD44 and activates pro-inflammatory signaling distinct from that induced by high-molecular-weight hyaluronan. The CD44-LMW-HA axis has been identified as a driver of inflammation in arthritis, lung injury, and organ fibrosis, adding another dimension to CD44 research beyond cancer.

CD44 as a Therapeutic Target

The concentration of CD44 on cancer stem cells has prompted research into anti-CD44 antibodies, CD44-targeted drug conjugates, and strategies that exploit CD44 internalization for intracellular drug delivery. For these therapeutic approaches to be evaluated rigorously, quantification of both membrane-bound and soluble CD44 in preclinical and clinical samples is essential. ELISA-based sCD44 measurement plays a supporting role in this work — tracking baseline tumor CD44 output and assessing how it changes when CD44-targeting therapies reduce surface expression or promote CD44 shedding.

Why Quantitative CD44 Data Matters

Qualitative surface staining of CD44 in cell lines or flow cytometry in blood samples tells researchers that CD44 is expressed. But quantifying how much soluble CD44 is circulating in patient plasma, or how its levels change in response to treatment, requires a different tool. That quantitative layer is what makes longitudinal clinical studies and therapy response monitoring with CD44 feasible.